Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into how the myeloma treatment landscape has transformed over the years with novel agents, and further discusses the challenge of relapse in this patient population. Dr Landgren comments on the importance of improving patient databases and using detailed cytogenetic information to better understand which patients are at risk of relapse, and further explains the value of implementing precision medicine to improve outcomes for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.